Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.

Mashari AlzahraniCarol StoberMichelle LiuArif AwanTerry L NgGregory PondBader AlshamsanLisa VandermeerMark Clemons

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)

The risk for SSEs was greatest in the first year after diagnosis of bone metastasis. Studies evaluating de-escalation and even stopping of BMAs with longer-term use may therefore be warranted.

Keyphrases

bone mineral density
preterm infants
prostate cancer
gestational age
soft tissue
bone loss
bone regeneration
randomized controlled trial
clinical trial
body composition
drug induced